BioWorld Asia

Dec. 22, 2004

Pharmos Crashes On Data From Phase III Brain Study

Once high on Pharmos Corp.'s cannabinoid-receptor drug for brain injury, investors came down hard following news that the compound failed in a pivotal Phase III trial.(BioWorld International) Read More

CAT Wins Court Battle Over Humira; Abbott Logs Appeal

Gene Therapy Boosts Hope For Blood Disease Therapies

Eyeing Cancer Drugs, Aphton Acquiring Igeneon For $81M

Europe Tackles Distinction In Similar Biotech Orphan Drugs

Phytopharm Product, Not Good For Pharma, Aimed At Foods

'Right Time': Bavarian Nordic To Form Cancer Vaccine Unit In U.S.

NicOx Taking Lead CINOD Into Phase III Osteoarthritis Program

Metabolic Jumps, Slides On Trial Data, Analyst Criticism

Santhera Raises Additional EUR7M In Second Closing Of Financing

Other News To Note

Today's news in brief

BioWorld

BioWorld briefs for March 16, 2026.

Precision psychiatry beyond, or before, biomarkers

BioWorld

There is broad agreement that psychiatric diagnoses in their current form are not reflective of any underlying biology, and that this is one of the things...

Keros reports beneficial effects of RKER-065 in ALS model

BioWorld Science

Keros Therapeutics Inc. has presented data regarding their activin receptor ligand trap, RKER-065, for the inhibition of the activin/myostatin signaling axis.

News in brief

BioWorld Asia

BioWorld Asia briefs for March 10, 2026

First-in-class POLG activator restores mtDNA across mutations

BioWorld Science

Researchers from Pretzel Therapeutics Inc. presented preclinical data of PX-578, a first-in-class POLG activator aimed at restoring mtDNA replication and...